Seminars in Oncology Nursing
Volume 25, Issue 2 , Pages 105-114 , May 2009

Expanding Indications for Stem Cell Transplantation

  • Kim Schmit-Pokorny

      Affiliations

    • Corresponding Author InformationAddress correspondence to Kim Schmit-Pokorny, RN, MSN, OCN®, Manager/Case Manager, Hematopoietic Cell Transplantation Program, University of Nebraska Medical Center, 987680 Nebraska Medical Center, Omaha, NE , 68198

References 

  1. Ferrera J, Anasetti C, Stadtmauer E, et al. Blood and marrow transplant clinical trials network state of the science symposium 2007. Biol Blood Marrow Transplant. 2007;13:1268–1285
  2. Schmit-Pokorny K. Blood and marrow transplantation: indications, procedure, process. In:  Ezzone S,  Schmit-Pokorny K editor. Blood and Marrow Stem Cell Transplantation: Principles, Practice, and Nursing Insights. Sudbury, MA: Jones and Bartlett Publishers; 2007;p. 75–107
  3. Niess D, Duffy K. Basic concepts of transplantation. In:  Ezzone S editors. Hematopoietic Stem Cell Transplantation. Pittsburgh, PA: Oncology Nursing Society; 2004;p. 13–21
  4. Lennard A, Jackson G. Science, medicine, and the future: stem cell transplantation. BMJ. 2000;321:433–437
  5. National Marrow Donor Program. Available at: www.marrow.org (accessed)
  6. Forman S. Planning and management for related and unrelated donor transplantation: day 10 to day 100. Blood Marrow Transplant Rev. 2007;17:5–7
  7. Ljungman P, Urbano-Ispizua A, Cavazzana-Calvo M, et al. Allogeneic and autologous transplantation for haematological diseases, solid tumours and immune disorders: definitions and current practice in Europe. Bone Marrow Transplant. 2006;37:439–449
  8. American Society for Blood and Marrow Transplantation. The role of cytotoxic therapy with hematopoietic stem cell transplantation in the treatment of diffuse large cell B-cell non-Hodgkin's lymphoma. ASBMT Position Statement. 2003. Available at: www.asbmt.org/policystat/policy.htm (accessed Sept 9, 2008).
  9. Hahn T, Wolff S, Czuczman M, et al. The role of cytotoxic therapy with hematopoietic stem cell transplantation in the therapy of diffuse large cell B-cell non-Hodgkin's lymphoma: an evidenced-based review. Biol Blood Marrow Transplant. 2001;7:308–331
  10. American Society for Blood and Marrow Transplantation. The role of cytotoxic therapy with hematopoietic stem cell transplantation in the therapy of acute myeloid leukemia in adults. ASBMT Position Statement. Biol Blood Marrow Transplant. 2008;14:135–136
  11. Oliansky D, Appelbaum F, Cassileth P, et al. The role of cytotoxic therapy with hematopoietic stem cell transplantation in the therapy of acute myelogenous leukemia in adults: an evidence-based review. Biol Blood Marrow Transplant. 2008;14:137–180
  12. American Society for Blood and Marrow Transplantation. The role of cytotoxic therapy with hematopoietic stem cell transplantation in the treatment of acute lymphoblastic leukemia in adults. ASBMT Position Statement. Biol Blood Marrow Transplant. 2006;12:368–369
  13. Hahn T, Wall D, Camitta B, et al. The role of cytotoxic therapy with hematopoietic stem cell transplantation in the therapy of acute lymphoblastic leukemia in adults: an evidenced-based review. Biol Blood Marrow Transplant. 2006;xx:1–30
  14. Pant S, Copelan E. Hematopoietic stem cell transplantation in multiple myeloma. Biol Blood Marrow Transplant. 2007;13:877–885
  15. Barlogie B, Tricot G, van Rhee F, et al. Long-term outcome results of the first tandem autotransplant trial for multiple myeloma. Br J Haematol. 2006;135:158–164
  16. American Society for Blood and Marrow Transplantation. The role of cytotoxic therapy with hematopoietic stem cell transplantation in the treatment of multiple myeloma. ASBMT Position Statement. 2003. Available at: www.asbmt.org/policystat/policy.htm (accessed Sept 9, 2008).
  17. Hahn T, Wingard J, Anderson K, et al. The role of cytotoxic therapy with hematopoietic stem cell transplantation in the therapy of multiple myeloma: an evidence-based review. Biol Blood Marrow Transplant. 2003;9:4–37
  18. American Society for Blood and Marrow Transplantation. The role of cytotoxic therapy with hematopoietic stem cell transplantation in the therapy of acute myeloid leukemia in children. ASBMT Position Statement. 2007. Biol Blood Marrow Transplant. 2007;13:500–501
  19. Oliansky D, Rizzo J, Aplan P, et al. The role of cytotoxic therapy with hematopoietic stem cell transplantation in the therapy of acute myeloid leukemia in children: an evidence-based review. Biol Blood Marrow Transplant. 2007;13:1–25
  20. American Society for Blood and Marrow Transplantation. The role of cytotoxic therapy with hematopoietic stem cell transplantation in the treatment of acute lymphoblastic leukemia in children. ASBMT Position Statement. Biol Blood Marrow Transplant 206;12:370–371.
  21. Hahn T, Wall D, Camitta B, et al. The role of cytotoxic therapy with hematopoietic stem cell transplantation in the therapy of acute lymphoblastic leukemia in children: an evidenced-based review. Biol Blood Marrow Transplant. 2005;xx:823–861
  22. Wingard J. Myelodysplastic syndromes: rejuvenating the senescent. Blood Marrow Transplant Rev. 2007;17:1
  23. Deeg H. Optimization of transplantation regimens for patients with myelodysplastic syndromes. Blood Marrow Transplant Rev. 2007;17:7–9
  24. Scott B. Maximizing treatment outcomes for MDS in the transplantation patient. Blood Marrow Transplant Rev. 2008;18:5–7
  25. Sorror M, Maris M, Sandmaier B, et al. Hematopoietic cell transplantation after nonmyeloablative conditioning for advanced chronic lymphocytic leukemia. J Clin Oncol. 2005;23:3819–3829
  26. Baccarani M, Saglio G, Goldman J, et al. Evolving concepts in the management of chronic myeloid leukemia: recommendation from an expert panel on behalf of the European LeukemiaNet. Blood. 2006;108:1809–1820
  27. Jabbour E, Cortes J, Kantarjian H, et al. Allogeneic stem cell transplantation for patients with chronic myeloid leukemia and acute lymphocytic leukemia after bcr-Abl kinase mutation-related imatinib failure. Blood. 2006;108:1421–1423
  28. Gratwohl A, Baldomero H, Demirer T, et al. Hematopoietic stem cell transplantation for solid tumors in Europe. Ann Oncol. 2004;15:653–660
  29. Frenette P, Atweh G. Sickle cell disease: old discoveries, new concepts, and future promise. J Clin Invest. 2007;117:850–858
  30. Bhatia M, Walters M. Hematopoietic cell transplantation for thalassemia and sickle cell disease: past, present and future. Bone Marrow Transplant. 2008;41:109–117
  31. Walters M, Patience M, Leisenring W, et al. Bone marrow transplantation for sickle cell disease. N Engl J Med. 1996;335:369–376
  32. Haller M, Viener H, Wasserfal C, et al. Autologous umbilical cord blood infusion for type 1 diabetes. Exp Hematol. 2008;36:710–715
  33. Rabusin M, Andolina M, Maximova N. Haematopoietic SCT in autoimmune diseases in children: rationale and new perspectives. Bone Marrow Transplant. 2008;41:S96–S99
  34. Marmont A. Allogeneic haematopoietic stem cell transplantation for severe autoimmune diseases: great expectations but controversial evidence. Bone Marrow Transplant. 2006;38:1–4
  35. Leung Y, Geddes M, Storek J, et al. Hematopoietic cell transplantation for Crohn's disease; is it time?. World J Gastroenterol. 2006;12:6665–6673
  36. Burt R. New indications in stem cell sources for transplantation for autoimmune diseases. Blood Marrow Transplant Rev. 2004;14:5–7
  37. Pavletic S, O'Dell J, Pirruccello S, et al. Intensive immunoablation and autologous blood stem cell transplantation in patients with refractory rheumatoid arthritis: The University of Nebraska experience. J Rheumatol. 2001;28(suppl 64):13–20
  38. Saccardi R, Mancardi G, Solari A, et al. Autologous HSCT for severe progressive multiple sclerosis in a multicenter trial: impact on disease activity and quality of life. Blood. 2005;105:2601–2607
  39. Le Blanc K, Ringden O. Immunobiology of human mesenchymal stem cells and future use in hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2005;11:321–334
  40. Friedman R, Betancur M, Boissel L, et al. Umbilical cord mesenchymal stem cells: adjuvants for human cell transplantation. Biol Blood Marrow Transplant. 2007;13:1477–1486
  41. Lazarus H, Koc O, Devine S, et al. Cotransplantation of HLA-identical sibling culture-expanded mesenchymal stem cells and hematopoietic stem cells in hematologic malignancy patients. Biol Blood Marrow Transplant. 2005;11:389–398
  42. Wirthlin L, Hess D, Zhou P, et al. Human stem cells for tissue repair. Biol Blood Marrow Transplant. 2008;14:151–153
  43. Sharp J, Murphy B, Jackson J, et al. Promises and pitfalls of stem cell therapy for promotion of bone healing. Clin Orthop Relat Res. 2005;435:52–61
  44. Bartley J, Carroll J. Stem cell therapy for cerebral palsy. Expert Opin Biol Ther. 2003;3:541–549
  45. Burt R, Loh Y, Pearce W, et al. Clinical applications of blood-derived and marrow-derived stem cells for nonmalignant diseases. JAMA. 2008;299:925–936
  46. Leung N, Griffin M, Dispenzieri A, et al. Living donor kidney and autologous stem cell transplantation for primary systemic amyloidosis (AL) with predominant renal involvement. Am J Transplant. 2005;5:1660–1670
  47. Gillmore J, Goodman H, Lachmann H, et al. Sequential heart and autologous stem cell transplantation for systemic AL amyloidosis. Blood. 2006;107:1227–1229

PII: S0749-2081(09)00021-7

doi: 10.1016/j.soncn.2009.03.002

Seminars in Oncology Nursing
Volume 25, Issue 2 , Pages 105-114 , May 2009

Article Tools

* Image Usage & Resolution